Sign Up Today and Learn More About Second Genome Stock

Invest in or calculate the value of your shares in Second Genome or other pre-IPO companies through EquityZen's platform.

Get Started

Second Genome Stock

Second Genome offers a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases.

About Second Genome Stock




San Francisco, CA, US

Notable Investor

Advanced Technology Ventures

Total Funding


Second Genome, a venture-backed Bay Area based life sciences company, is committed to improving the quality of human health through microbiome-based personalized medicine. Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. Working with academic and commercial collaborators, Second Genome is developing novel diagnostic tools and therapies for unmet needs in gastrointestinal disorders. The company has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. Second Genome entered into the first ever big pharmaceutical partnership focused on microbiome drug discovery with Janssen Biotech, Inc. in June 2013 for new treatments for ulcerative colitis.

Second Genome Press Mentions

Stay in the know about the latest news on Second Genome

Investors in Second Genome

Discover investors in Second Genome stock and explore their portfolio companies

Second Genome Management

Leadership team at Second Genome

Chief Scientific Officer

Karim Dabbagh

Co-Founder & SVP, Platform Technologies

Janet A. Warrington

Locked Features

Join now and verify your accreditation status to gain access to:

  • Second Genome current valuation
  • Second Genome stock price
  • Available deals in Second Genome and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Second Genome stock?

Accredited investors can buy pre-IPO stock in companies like Second Genome through EquityZen funds. These investments are made available by existing Second Genome shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Second Genome stock?

Shareholders can sell their Second Genome stock through EquityZen's private company marketplace. EquityZen's network includes over 300K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."